Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer. [electronic resource]
Producer: 20150302Description: 682-90 p. digitalISSN:- 1573-0646
- Adolescent
- Adult
- Antibodies, Monoclonal -- adverse effects
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents, Phytogenic -- therapeutic use
- Camptothecin -- analogs & derivatives
- Colorectal Neoplasms -- drug therapy
- Disease Progression
- Disease-Free Survival
- Female
- Humans
- Irinotecan
- Male
- Maximum Tolerated Dose
- Membrane Glycoproteins -- antagonists & inhibitors
- Middle Aged
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.